8.97 USD
-0.37
3.96%
At close Feb 6, 4:00 PM EST
Pre-market
8.87
-0.10
1.11%
1 day
-3.96%
5 days
25.45%
1 month
16.64%
3 months
32.89%
6 months
18.03%
Year to date
18.97%
1 year
122.58%
5 years
-85.12%
10 years
-85.12%
 

About: Mind Medicine Inc is a biopharmaceutical company. The company produces to treat brain health disorders. The company discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances. The firm is having an approach towards developing the next generation of psychedelic-inspired medicines and therapies.

Employees: 57

0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

79% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 28

79% more call options, than puts

Call options by funds: $4.76M | Put options by funds: $2.67M

43% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 21

3% more funds holding

Funds holding: 150 [Q2] → 155 (+5) [Q3]

2.8% more ownership

Funds ownership: 58.07% [Q2] → 60.87% (+2.8%) [Q3]

6% less capital invested

Capital invested by funds: $301M [Q2] → $282M (-$18.9M) [Q3]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q2] → 2 (-1) [Q3]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$20
123%
upside
Avg. target
$30
229%
upside
High target
$55
513%
upside

4 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Patrick Trucchio
42% 1-year accuracy
74 / 175 met price target
513%upside
$55
Buy
Reiterated
31 Jan 2025
Evercore ISI Group
Gavin Clark-Gartner
36% 1-year accuracy
4 / 11 met price target
156%upside
$23
Outperform
Initiated
28 Jan 2025
Chardan Capital
Rudy Li
50% 1-year accuracy
2 / 4 met price target
123%upside
$20
Buy
Initiated
20 Dec 2024
Oppenheimer
Francois Brisebois
51% 1-year accuracy
19 / 37 met price target
123%upside
$20
Outperform
Reiterated
17 Dec 2024

Financial journalist opinion

Neutral
Business Wire
3 days ago
MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference: Oppenheimer 35th Annual Healthcare Life Sciences Conference Format: Fireside Chat and 1x1 Meetings Date: February 12, 2025 at 9:20 AM ET Location:.
MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Neutral
Business Wire
1 week ago
MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that the first patient has been dosed in Panorama, its second Phase 3 study evaluating MM120 ODT, a proprietary, pharmaceutically optimized form of LSD for the treatment generalized anxiety disorder (GAD). The Panorama study will evaluate the efficacy and safety o.
MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder
Positive
The Motley Fool
1 month ago
Why Mind Medicine Stock Is Soaring Today
Mind Medicine (MNMD 8.97%) stock is posting big gains in Tuesday's trading. The biotech company's share price was up 8.7% as of 2 p.m.
Why Mind Medicine Stock Is Soaring Today
Positive
Zacks Investment Research
1 month ago
MindMed Stock Skyrockets 94% Year to Date: What's Driving It?
2024 was a transformational year for MNMD as it executed many important milestones.
MindMed Stock Skyrockets 94% Year to Date: What's Driving It?
Positive
Zacks Investment Research
1 month ago
5 Biotech Breakthrough Stocks to Watch in 2025
After a decent first half, the drug and biotech sector saw a major downturn in the second half due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointment of Robert F. Kennedy Jr., a vaccine skeptic, as the head of Health and Human Services.
5 Biotech Breakthrough Stocks to Watch in 2025
Neutral
Business Wire
1 month ago
MindMed to Be Added to the Nasdaq Biotechnology Index
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will be added to the Nasdaq Biotechnology Index (NBI), effective at market open on Monday, December 23, 2024. “2024 has been a transformational year for MindMed. We've successfully executed many important milestones, including raising approximately $250 million.
MindMed to Be Added to the Nasdaq Biotechnology Index
Neutral
Business Wire
1 month ago
MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that the first patient has been dosed in its Phase 3 Voyage study of MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD) for the treatment of GAD. Voyage is the first of two Phase 3 studies in GAD evaluating the efficacy and safety of MM120 ODT v.
MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)
Neutral
Business Wire
1 month ago
MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it presented encore data from its Phase 2b study of MM120 (lysergide D-tartrate or LSD), the Company's lead product candidate in generalized anxiety disorder, at the ACNP 2024 Congress taking place December 8 – 11 in Phoenix, AZ. Details of the presentations are a.
MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress
Neutral
Business Wire
2 months ago
MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD), has been granted an Innovation Passport for the potential treatment of GAD under ILAP by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA). The Innovation Passport is the.
MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)
Neutral
Business Wire
2 months ago
MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Javier A. Muniz, M.D., as Vice President of Research and Development (R&D) Strategy. In his new role, Dr. Muniz will drive innovation and growth of MindMed's R&D operations as the Company prepares to initiate three Phase 3 studies of MM120 or.
MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy
Charts implemented using Lightweight Charts™